Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Ventas (NYSE:VTR) Slips for a Second Day as Higher Treasury Yields Pressure Senior Housing REITs

Ventas issued no company announcement on Friday. The latest analyst move was positive. UBS raised its price target to $99 from $90 on November 11, which implies about 11% upside from Friday's close, and Morgan Stanley reaffirmed a Hold rating on November 10.

Nitish Kishor | 16 November 2026

Welltower (NYSE:WELL) Dips on the S&P 500 as Treasury Yields Weigh on REITs Despite a UBS Target Hike

Treasury yields rose on Friday, and higher yields tend to pressure real estateInvestmenttrusts because they raise borrowing costs and make dividend-paying stocks less attractive next to bonds. Peers in senior housing and net-lease real estate, including Ventas (NYSE:VTR) and Realty Income (NYSE:O), also finished …

Nitish Kishor | 16 November 2026

World Kinect (NYSE:WKC) Rises as Investors Buy Fuel Distributors Amid Tight Diesel Markets

The broader market was weak, with the S&P 500 down 0.4% and the Russell 2000 down 0.3%, so World Kinect's gain was a clear outperformance.

Nitish Kishor | 16 November 2026

Destination XL 2026 Annual Meeting: Reverse Split Vote Set

Destination XL Group, Inc. filed a definitive proxy statement on November 16, 2026, soliciting stockholder votes for its 2026 Annual Meeting to be held on December 17, 2026, at the company's Canton, Massachusetts headquarters.

Shwetambri Chauhan | 16 November 2026

StandardAero Adds $600M Term Loan, Launches $350M ASR

StandardAero, Inc. filed an 8-K on November 16, 2026, disclosing a $600 million incremental term loan facility executed on November 13, 2026, and a $350 million accelerated share repurchase agreement entered into the same day with Morgan Stanley & Co. LLC.

Shwetambri Chauhan | 16 November 2026

Minerva Neurosciences Revises KOL Transcript on Roluperidone

Minerva Neurosciences, Inc. filed a Form 8-K on November 16, 2026, furnishing a revised transcript of a key opinion leader event held on November 12, 2026, related to roluperidone, its product candidate for negative symptoms in schizophrenia patients.

Nitish Kishor | 16 November 2026

Bruker Appoints Eicke Latz to Board, Declares Dividend

Bruker Corporation filed a Form 8-K on November 16, 2026, disclosing the appointment of Eicke Latz MD PhD to its Board of Directors effective January 1, 2027, and the declaration of a quarterly cash dividend of $0.05 per share on its common stock.

Shwetambri Chauhan | 16 November 2026

Mentari Therapeutics Files Post-Merger Financials for Q3 2026

Mentari Therapeutics, Inc. filed a Form 8-K on November 16, 2026, submitting unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2026, following its merger closing on November 6, 2026.

Aditi Sarkar | 16 November 2026

Timothy White Joins AirJoule Board, Ajay Agrawal Exits

AirJoule Technologies Corporation filed a Form 8-K on November 16, 2026, disclosing a director appointment and resignation effective November 12, 2026, as well as the release of its third-quarter 2026 financial and operational results.

Vinay Lochav | 16 November 2026

Xtant Medical Reports Q3 2026 Financial Results

Xtant Medical Holdings, Inc. filed a Form 8-K with the SEC on November 16, 2026, announcing its financial results for the third quarter of 2026 via a press release furnished as Exhibit 99.1.

Vinay Lochav | 16 November 2026
Support

Hi! How can we help you today?

Loading…